Key steps in pursuing a strategy of active surveillance for very low-risk prostate cancer
Christopher P. Evans, MD, discusses his active surveillance protocol with J. Brantley Thrasher, MD.
In this interview, Christopher P. Evans, MD, discusses the use of active surveillance in men with low-risk prostate cancer. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. He was interviewed by Urology Times® Editorial Consultant J. Brantley Thrasher, MD, executive director of the American Board of Urology, Charlottesville, Virginia.
More videos:
App facilitates assessment of urologic chronic pelvic pain syndrome
Testosterone therapy does not appear to worsen outcomes in men with COVID-19
HIFU for prostate cancer: How it works, criteria for treatment, and contraindications
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
